Alaunos Therapeutics Inc [NASDAQ: TCRT] price surged by 7.84 percent to reach at $0.29.
A sum of 23844483 shares traded at recent session while its average daily volume was at 142.59K shares. Alaunos Therapeutics Inc shares reached a high of $4.59 and dropped to a low of $3.67 until finishing in the latest session at $3.99.
The one-year TCRT stock forecast points to a potential upside of 99.65. The average equity rating for TCRT stock is currently 3.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Alaunos Therapeutics Inc [TCRT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TCRT shares is $1125.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TCRT stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Alaunos Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 04, 2022.
The Price to Book ratio for the last quarter was 2.26, with the Price to Cash per share for the same quarter was set at 1.31.
TCRT Stock Performance Analysis:
Alaunos Therapeutics Inc [TCRT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 51.71. With this latest performance, TCRT shares gained by 82.19% in over the last four-week period, additionally plugging by 55.25% over the last 6 months – not to mention a rise of 109.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TCRT stock in for the last two-week period is set at 78.49, with the RSI for the last a single of trading hit 0.36, and the three-weeks RSI is set at 0.31 for Alaunos Therapeutics Inc [TCRT]. The present Moving Average for the last 50 days of trading for this stock 2.45, while it was recorded at 3.16 for the last single week of trading, and 2.51 for the last 200 days.
Insight into Alaunos Therapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Alaunos Therapeutics Inc [TCRT] shares currently have an operating margin of -67266.67% and a Gross Margin at -3966.67%. Alaunos Therapeutics Inc’s Net Margin is presently recorded at -66550.00%.
Alaunos Therapeutics Inc (TCRT) Capital Structure & Debt Analysis
According to recent financial data for Alaunos Therapeutics Inc. ( TCRT), the Return on Equity (ROE) stands at -107.45%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -84.84%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Alaunos Therapeutics Inc’s Return on Invested Capital (ROIC) is -109.07%, showcasing its effectiveness in deploying capital for earnings.
Alaunos Therapeutics Inc (TCRT) Efficiency & Liquidity Metrics
Based on Alaunos Therapeutics Inc’s (TCRT) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Alaunos Therapeutics Inc (TCRT) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Alaunos Therapeutics Inc. (TCRT) effectively leverages its workforce, generating an average of -$3990000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 3.48% and a Quick Ratio of 3.48%, indicating strong ability to cover short-term liabilities.
TCRT Stock EPS
With the latest financial reports released by the company, Alaunos Therapeutics Inc posted -6/share EPS, while the average EPS was predicted by analysts to be reported at -6.6/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.6. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TCRT.
Alaunos Therapeutics Inc [TCRT] Institutonal Ownership Details
There are presently around $4.76%, or 5.33%% of TCRT stock, in the hands of institutional investors. The top three institutional holders of TCRT stocks are: MSD PARTNERS, L.P. with ownership of 1.01 million shares, which is approximately 6.3082%. VANGUARD GROUP INC, holding 0.63 million shares of the stock with an approximate value of $$0.44 million in TCRT stocks shares; and VANGUARD GROUP INC, currently with $$0.16 million in TCRT stock with ownership which is approximately 1.3892%.
